55.71 -0.08 (-0.14%)
After hours: 4:11PM EDT
|Bid||55.00 x 800|
|Ask||59.00 x 1200|
|Day's Range||55.01 - 56.01|
|52 Week Range||45.31 - 67.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.50|
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
Seattle Genetics, Inc. (SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. “Roger’s appointment reflects the growing importance of late-stage clinical drug development at Seattle Genetics as we transition to a global, multi-product oncology company,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics.
Seattle Genetics, Inc. today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, from June 1-5, 2018.
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson ...
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences.
Bothell's future as a thriving biotech hub hinges on its ability to compete with Seattle's Lake Union area. That's prompting changes that aim to make Bothell's business district a great place to work and play.
Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m.
The company is the state's largest biotech, and has been growing quickly. Now, it's on the hunt for another building. Seattle Genetics is looking for a building that includes office and lab space. The company will likely remodel the new building.
On a per-share basis, the Bothell, Washington-based company said it had a loss of 73 cents. Losses, adjusted for non-recurring costs, were 61 cents per share. The results did not meet Wall Street expectations. ...
Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2018. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, and progress with its late-stage clinical programs and pipeline of targeted therapies for cancer.
The Seattle-area’s largest biotech already has a footprint of about 500,000 square feet, which includes seven office buildings in Bothell, a manufacturing facility in North Creek and a Seattle office.
Seattle Genetics, Inc. today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate platform technologies as well as its emerging immuno-oncology pipeline.
Seattle Genetics, Inc. announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
“This marks the first time in four decades and 10 different attempts to replace one of the most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate , for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors .